trending Market Intelligence /marketintelligence/en/news-insights/trending/e_vFLipKeKvNK8gPisJj9Q2 content esgSubNav
In This List

Biogen to buy back $5B of common stock

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Biogen to buy back $5B of common stock

Biogen Inc.'s board authorized to repurchase up to $5 billion of the company's common stock.

The 2019 share repurchase program has no expiration date, the Cambridge, Mass.-based biotechnology company said.

Biogen, which focuses on neurodegenerative diseases, said the new repurchase program is in addition to the about $1.7 billion remaining under a $3.5 billion buyback program launched in August 2018.

Biogen stocks dropped more than 29% after news that the company and Japan's Eisai Co. Ltd. will be discontinuing two late-stage clinical trials of their Alzheimer's drug aducanumab. Biogen shares fell to $226.88 as of the close of U.S. trading March 21, down 29.23%.